If you or someone you know is in crisis, call or text 988. In an emergency, call 911.

Opioid Overdose and Naloxone

In brief

When opioids affect breathing

The Substance Abuse and Mental Health Services Administration (SAMHSA) describes an opioid overdose as an emergency in which the effects of opioids can become life-threatening. The National Institute on Drug Abuse (NIDA) connects the slowing of breathing to opioid effects on the brain stem, an area of the brain that controls basic functions, including breathing and heart rate.

SAMHSA describes several circumstances in which overdose can occur, including accidental errors involving a prescription and use of an opioid prescribed for another person. Those examples concern the exposure. The signs SAMHSA lists concern what may be happening to a person's breathing and ability to respond. The agency's description includes circumstances that can arise during medical care and outside it.

SAMHSA describes overdose reversal medication as relevant for some people after emergency care for opioid poisoning and for some people who have had a period without opioid use. In NIDA's account of treatment and recovery, a period without use can change the body's response to a substance it had adapted to. This is part of the context federal sources give for discussing overdose alongside ongoing care.

Signs federal agencies list

SAMHSA's list of possible signs includes a person who does not wake or respond to a voice or touch and breathing that is abnormal, very slow, or stopped. SAMHSA also lists changes in appearance, such as very small pupils or a bluish color around the lips or nose. The list includes changes a person nearby might see as well as changes in how the person responds.

NIDA's fact sheet on naloxone also describes slow or shallow breathing, unconsciousness, and very small pupils among possible signs. NIDA's list adds an inability to speak, limp arms and legs, a faint heartbeat, and vomiting, along with changes in color such as pale skin or purple lips or fingernails. Shallow breathing describes a change in the depth of a breath, while slow breathing describes a change in its pace.

SAMHSA describes an opioid overdose as requiring immediate emergency attention. In SAMHSA's account of overdose response, obtaining medical attention quickly remains critical after a reversal medicine is given.

What naloxone does

NIDA calls naloxone an opioid antagonist. A receptor is a place on a cell where a substance can attach and affect what the cell does. In NIDA's explanation of the mechanism, naloxone attaches to opioid receptors and blocks the effects of opioids at those sites. NIDA says this can restore breathing that has slowed or stopped during an opioid overdose.

The NIDA fact sheet describes this action as specific to opioids. The term overdose reversal describes the medication's effect on the acute episode. NIDA describes nasal spray and injectable forms of naloxone. Both forms contain the same active medicine. NIDA says naloxone has no effect when there are no opioids in the body. The description of which receptors it affects explains the place of this medicine in emergency care for an opioid overdose.

Why the reversal is temporary

NIDA describes naloxone as active for 30 to 90 minutes and notes that many opioids stay in the body longer. That difference helps explain why NIDA describes overdose effects as able to return as naloxone wears off. The NIDA fact sheet on emergency care includes monitoring after reversal to detect whether breathing slows or stops again.

NIDA notes that a person who is physically dependent on opioids may also have withdrawal symptoms after receiving naloxone, including nausea, sweating, or shaking. Physical dependence means the body has adapted to repeated exposure, and withdrawal describes what happens when that exposure is interrupted. The NIDA fact sheet distinguishes physical dependence from addiction. It describes physical dependence in some people receiving prescribed medicines for pain, while its description of addiction centers on substance use becoming difficult to control even when it causes harm. This helps explain why the condition of the person can change during the same emergency, as NIDA's discussion of dependence and withdrawal describes.

How nonprescription approval came about

In 2023, the U.S. Food and Drug Administration (FDA) approved the first naloxone nasal spray for nonprescription use. The FDA's announcement describes a change in the approval for an individual product that previously required a prescription. The agency distinguished that decision from the prescription status of other formulations in the same announcement.

The FDA's account of its review says the application included evidence of how people understood the proposed labeling. Before the approval, the FDA developed and tested model label information with simple pictures for nonprescription products. In 2022, the FDA had announced a preliminary assessment that certain formulations of naloxone might be suitable for nonprescription use. The earlier work concerned how to evaluate possible nonprescription products. The later approval concerned the specific formulation in the application.

SAMHSA describes public education on overdose in its overview of the Overdose Prevention and Response Toolkit. The audiences it names include first responders, people prescribed opioid medicines, families, and communities. SAMHSA describes updating the toolkit in 2024 with guidance on recognizing and responding to an overdose. In the agency's account, the public education material serves as a foundation for training audiences who may encounter overdose in different settings.

Emergency reversal and ongoing care

NIDA describes naloxone in connection with an opioid overdose and describes emergency clinicians as able to connect people to ongoing care after a reversal. The page on medications used in treating opioid use disorder explains the different purpose of medications prescribed for the underlying condition. The page on recovery support describes peer and community support services people may encounter as they continue with care.

Sources